233 related articles for article (PubMed ID: 32221476)
61. Inosine triphosphate pyrophosphohydrolase (ITPA) polymorphic sequence variants in Chinese ALL children and possible association with mercaptopurine related toxicity.
Ma X; Zheng J; Jin M; Li W; Gao C; Zhang D; Chen Y; Li X; Xie J
Int J Clin Exp Pathol; 2014; 7(7):4552-6. PubMed ID: 25120852
[TBL] [Abstract][Full Text] [Related]
62. Mercaptopurine induced myelosuppression in a child with a
Gupta N; Magatha LS; Jayaraman D; Scott JX; Antony SB; Koshy T
J Oncol Pharm Pract; 2023 Jun; 29(4):999-1001. PubMed ID: 36341754
[TBL] [Abstract][Full Text] [Related]
63. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
[TBL] [Abstract][Full Text] [Related]
64. Association of Multiple Gene Polymorphisms Including Homozygous NUDT15 R139C With Thiopurine Intolerance During the Treatment of Acute Lymphoblastic Leukemia.
Kudo K; Sato T; Takahashi Y; Yuzawa K; Kobayashi A; Kamio T; Sasaki S; Shimada J; Otani K; Tusjimoto S; Kato M; Toki T; Terui K; Ito E
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1173-e1176. PubMed ID: 33625081
[TBL] [Abstract][Full Text] [Related]
65. Pharmacogenomics in acute lymphoblastic leukemia.
Lee SHR; Yang JJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):229-236. PubMed ID: 29050696
[TBL] [Abstract][Full Text] [Related]
66. Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population.
Ramalingam R; Kaur H; Scott JX; Sneha LM; Arun Kumar GP; Srinivasan A; Paul SF
Pharmacogenomics; 2021 May; 22(7):401-411. PubMed ID: 33876659
[No Abstract] [Full Text] [Related]
67. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
[TBL] [Abstract][Full Text] [Related]
68. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
[TBL] [Abstract][Full Text] [Related]
69. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
[TBL] [Abstract][Full Text] [Related]
70. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis.
Jena A; Jha DK; Kumar-M P; Kasudhan KS; Kumar A; Sarwal D; Mishra S; Singh AK; Bhatia P; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):491-501. PubMed ID: 33682590
[No Abstract] [Full Text] [Related]
71. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.
Stocco G; Yang W; Crews KR; Thierfelder WE; Decorti G; Londero M; Franca R; Rabusin M; Valsecchi MG; Pei D; Cheng C; Paugh SW; Ramsey LB; Diouf B; McCorkle JR; Jones TS; Pui CH; Relling MV; Evans WE
Hum Mol Genet; 2012 Nov; 21(21):4793-804. PubMed ID: 22846425
[TBL] [Abstract][Full Text] [Related]
72. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
73. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
74. NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia.
Yoshida M; Nakabayashi K; Yang W; Sato-Otsubo A; Tsujimoto SI; Ogata-Kawata H; Kawai T; Ishiwata K; Sakamoto M; Okamura K; Yoshida K; Shirai R; Osumi T; Moriyama T; Nishii R; Takahashi H; Kiyotani C; Shioda Y; Terashima K; Ishimaru S; Yuza Y; Takagi M; Arakawa Y; Kinoshita A; Hino M; Imamura T; Hasegawa D; Nakazawa Y; Okuya M; Kakuda H; Takasugi N; Inoue A; Ohki K; Yoshioka T; Ito S; Tomizawa D; Koh K; Matsumoto K; Sanada M; Kiyokawa N; Ohara A; Ogawa S; Manabe A; Niwa A; Hata K; Yang JJ; Kato M
Blood Adv; 2021 Dec; 5(23):5420-5428. PubMed ID: 34662904
[TBL] [Abstract][Full Text] [Related]
75. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
76. 6-Mercaptopurine-associated Sinusoidal Obstructive Syndrome During Interim Maintenance I: A Case Report.
Voelz K; Miller G; Lee-Miller C
J Pediatr Hematol Oncol; 2024 Jul; 46(5):e317-e321. PubMed ID: 38775421
[TBL] [Abstract][Full Text] [Related]
77. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.
Choi R; Sohn I; Kim MJ; Woo HI; Lee JW; Ma Y; Yi ES; Koo HH; Lee SY
Br J Clin Pharmacol; 2019 Jul; 85(7):1585-1597. PubMed ID: 30927276
[TBL] [Abstract][Full Text] [Related]
78. [Association between polymorphism of NUDT15 gene and hepatotoxicity induced by 6-MP in children with acute lymphoblastic leukemia].
Wang X; Wang W
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Dec; 38(12):1258-1261. PubMed ID: 34839520
[TBL] [Abstract][Full Text] [Related]
79. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.
Chiengthong K; Ittiwut C; Muensri S; Sophonphan J; Sosothikul D; Seksan P; Suppipat K; Suphapeetiporn K; Shotelersuk V
Haematologica; 2016 Jan; 101(1):e24-6. PubMed ID: 26405151
[No Abstract] [Full Text] [Related]
80. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
